Atlas Trials

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Clinical trial NCT06639074 · RECRUITING

Trial details

NCT number
NCT06639074
Sponsor
Mayo Clinic
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Advanced Fallopian Tube CarcinomaAdvanced Fallopian Tube High Grade Serous AdenocarcinomaAdvanced Ovarian CarcinomaAdvanced Ovarian CarcinosarcomaAdvanced Ovarian Clear Cell AdenocarcinomaAdvanced Ovarian Endometrioid AdenocarcinomaAdvanced Ovarian High Grade Serous AdenocarcinomaAdvanced Primary Peritoneal CarcinomaAdvanced Primary Peritoneal High Grade Serous AdenocarcinomaFallopian Tube CarcinosarcomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma
Start date
2024-11-08
Primary completion
2027-12-31
Enrollment
78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.